← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Tesamorelin × CJC-1295 × Sermorelin × 3 of 4 selected View comparison

Tesamorelin

Stabilised GHRH analogue

Remove
VS

CJC-1295

Modified GHRH analogue

Remove
VS

Sermorelin

GHRH fragment analogue

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target TesamorelinCJC-1295Sermorelin
✓ ✓ ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Tesamorelin / CJC-1295 / Sermorelin → GHRHR (direct target) → Pituitary → GH → IGF-1 Steps after GHRHR are the general GH-axis cascade, not a compound-specific demonstrated effect.

What These Compounds Share

Shared direct targets (all selected compounds)
GHRHR
Shared research line

All selected compounds are catalogued under Peak.

Shared pathway tags
GHRHRGH

Key Differences

Tesamorelin Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. A stabilised GHRH analogue with substantial human clinical characterisation.
CJC-1295 Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. A modified GHRH analogue without the albumin-binding DAC modification.
Sermorelin Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. The catalogue compound closest to the native active GHRH(1-29) fragment.

Compound Detail

Tesamorelin
What is it?
A lab-made version of a hormone that tells your pituitary gland to release growth hormone.
What are people researching/using it for?
Approved and studied for reducing abdominal fat in specific medical contexts.
Other uses being trialed
General growth-hormone axis research
Worth knowing
Approved for a specific indication in branded formulations, backed by two pivotal randomized trials (404 and 412 HIV-positive participants) showing significant visceral-fat reduction versus placebo over 26 weeks; broader research (e.g. cognition, see below) continues in other contexts with less consistently positive results.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Stimulates GHRH receptors on pituitary somatotrophs, promoting endogenous GH secretion and downstream IGF-1 signalling.
Synthetic peptide · Synthetic analogue
Primary Targets & Biological System
GH axis / pituitary signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A stabilised analogue of growth-hormone-releasing hormone (GHRH) that binds the GHRH receptor on somatotroph cells in the pituitary gland, stimulating them to release the body's own growth hormone (GH) in a pulsatile pattern similar to natural GHRH signalling. Released GH then acts on the liver and other tissues to stimulate IGF-1 production, which mediates many of GH's downstream effects. Because this mechanism works through the body's own pituitary GH release rather than delivering synthetic GH directly, its effects depend on a functioning pituitary gland.
Research Areas
GH-axis physiologyVisceral adipose tissueMetabolic/endocrine research
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Short-lived; not displayed as a single universal value without a direct source.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
A stabilised GHRH analogue with substantial human clinical characterisation.
Considerations
Research Limitations
Approved for a specific indication in branded formulations, backed by two pivotal randomized trials (404 and 412 HIV-positive participants) showing significant visceral-fat reduction versus placebo over 26 weeks; broader research (e.g. cognition, see below) continues in other contexts with less consistently positive results.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Cognitive function in aging/HIV
A randomized, open-label Phase II trial (73 participants, multicenter -- UC San Diego, UCSF, USC) tested tesamorelin for neurocognitive function in adults with HIV and abdominal obesity. The treatment group showed a trend toward improvement, but the difference versus standard-of-care was not statistically significant -- an example of a real trial with a null result, included here for that reason rather than to suggest a benefit was shown.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
Tesamorelin · A$149.95 A$169.95
Browse products →
View Research Sources (4) →
EGRIFTA (tesamorelin) Prescribing Information
FDA Prescribing Information — EGRIFTA · Regulatory document Human

Supports: mechanism_summary, primary_targets

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension
Journal of Acquired Immune Deficiency Syndromes, 2010 · Human Human · 404 HIV-infected patients with excess abdominal fat · Subcutaneous · PMID 20101189 · DOI 10.1097/QAI.0b013e3181cbdaff

12-month study, 2 sequential phases (6-month double-blind 2:1 tesamorelin:placebo, then 6-month open extension). VAT decreased 10.9% (tesamorelin) vs 0.6% (placebo) at 6 months (P<0.0001); ~18% reduction with 12 months continuous use.

Supports: research_limitations, human_administration_status

Metabolic effects of a growth hormone-releasing factor in patients with HIV
New England Journal of Medicine, 2007 · Human Human · 412 HIV-positive patients (86% men) · Subcutaneous, daily · PMID 18057338 · DOI 10.1056/NEJMoa072375

Visceral adipose tissue decreased 15.2% (tesamorelin) vs increased 5.0% (placebo), P<0.001.

Supports: research_limitations, human_administration_status

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
Journal of Infectious Diseases, 2025 · Human Human · 73 participants (HIV, abdominal obesity), multicenter (UC San Diego, UCSF, USC) · Subcutaneous · PMID 39813152 · DOI 10.1093/infdis/jiaf012

Open-label Phase 2, randomized 3:2 tesamorelin vs standard of care over 6 months. Trend toward improved neurocognitive performance (P=.060) but between-group difference not significant (P=.673) -- a genuine null result.

Supports: experimental_research

CJC-1295
What is it?
A modified version of a natural hormone-releasing signal that prompts the body to release its own growth hormone.
What are people researching/using it for?
Studied for its role in stimulating natural growth hormone release.
Other uses being trialed
General growth-hormone axis research
Worth knowing
Human research for the exact No-DAC molecule is insufficient/not established. The commonly cited 5.8-8.1 day half-life belongs to CJC-1295 WITH DAC and is not transferred to this No-DAC compound; the frequently repeated "~30 minute" figure is also not presented as established human PK without a direct exact-compound source.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A modified GHRH analogue, without the albumin-binding DAC modification, that stimulates GHRH receptors and GH-axis signalling.
Synthetic peptide · 29 amino acids · Synthetic analogue
Also known as: Modified GRF(1-29)
Primary Targets & Biological System
GH axis / pituitary signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A modified analogue of GHRH(1-29) that, like tesamorelin and sermorelin, binds the GHRH receptor on the pituitary to stimulate endogenous growth hormone release. Without the DAC (drug affinity complex) modification that gives the related compound CJC-1295 WITH DAC its long albumin-binding half-life, this no-DAC version is expected to behave pharmacokinetically more like other short-acting GHRH(1-29) analogues -- but the exact human PK for this specific molecule has not been established in the literature reviewed for this dataset.
Research Areas
GH secretionPituitary signallingGH/IGF-1 axis
Research Profile
Human administration: None identified Preclinical: Limited
Pharmacokinetics
Not adequately established for the exact No-DAC molecule.
Research Routes
Subcutaneous (research contexts) (descriptive only — not administration or dosing guidance)
Key Differentiator
A modified GHRH analogue without the albumin-binding DAC modification.
Considerations
Research Limitations
Human research for the exact No-DAC molecule is insufficient/not established. The commonly cited 5.8-8.1 day half-life belongs to CJC-1295 WITH DAC and is not transferred to this No-DAC compound; the frequently repeated "~30 minute" figure is also not presented as established human PK without a direct exact-compound source.
Availability & Sources
Current Vital Edge Testing
Available As (Vital Edge Science)
CJC-1295 · A$84.95 A$99.95
Browse products →

Source review pending for this compound — no citation on file yet.

Sermorelin
What is it?
The core active portion of the body's own growth-hormone-releasing hormone.
What are people researching/using it for?
Studied for stimulating natural growth hormone release.
Other uses being trialed
General growth-hormone axis research
Worth knowing
Short-lived pharmacokinetics; an exact half-life value is only shown when directly supported by source data -- the human studies on file demonstrate dose-response and comparative PK behaviour, not a single settled half-life figure.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Represents the biologically active N-terminal portion of GHRH and stimulates pituitary GH secretion.
29-amino-acid peptide · 29 amino acids · Synthetic, corresponds to the active N-terminal fragment of native GHRH
Primary Targets & Biological System
GH axis / pituitary signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Sermorelin is the biologically active N-terminal 29-amino-acid fragment of native GHRH -- shorter analogues like tesamorelin and CJC-1295 are themselves modifications built on this same active fragment. It binds the GHRH receptor on the pituitary the same way full-length GHRH does, stimulating endogenous growth hormone release, but without the stabilising modifications those other analogues carry, which is generally understood to give it a shorter duration of action -- though an exact human half-life for sermorelin specifically has not been established in the sources reviewed here. Human dose-response research confirms significant GH release at 10-100 mcg doses, and separate SC research found no meaningful PK difference between native GHRH(1-29) and a modified analogue -- direct human evidence for the mechanism, even without a settled half-life figure.
Research Areas
GH secretionPituitary functionGH-axis physiology
Research Profile
Human administration: Available Preclinical: Available
Pharmacokinetics
Short-lived; not displayed as an exact value without direct support.
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
The catalogue compound closest to the native active GHRH(1-29) fragment.
Considerations
Research Limitations
Short-lived pharmacokinetics; an exact half-life value is only shown when directly supported by source data -- the human studies on file demonstrate dose-response and comparative PK behaviour, not a single settled half-life figure.
Availability & Sources
Current Vital Edge Testing
No current batch testing on file yet.
Available As (Vital Edge Science)
Sermorelin · A$79.95 A$99.95
Browse products →
View Research Sources (2) →
Low-dose growth hormone-releasing hormone tests: a dose-response study
European Journal of Endocrinology, 1994 · Human Human · 10 adult male volunteers (plus 5 additional at lower doses) · Intravenous bolus · PMID 7921207 · DOI 10.1530/eje.0.1310238

Significant GH response to 10 and 100 mcg doses (not 1 mcg); time-to-peak GH was dose-dependent (7.0 min at 1 mcg, 15.8 min at 10 mcg, 24.8 min at 100 mcg).

Supports: mechanism_summary

Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man
Peptides, 1989 · Human Human · Normal male volunteers · Subcutaneous · PMID 2546126 · DOI 10.1016/0196-9781(89)90065-x

No significant difference in GHRH(1-29) immunoreactivity, AUC, or plasma disappearance rate between native GHRH(1-29) and a stabilised agonist analogue; GH response was also similar between the two.

Supports: mechanism_summary

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.